Among patients with diabetes there was a reduction in sulfonylurea treatment (10.7% vs 3.6%, p < 0.05 patients who stopped Sulfonylurea) and increase in GLP-1 (16.4% vs 11.2%, p < 0.05 patients who started GLP-1), representing better adherence with guidelines and with patient safety in the pharmacist consultation group. Here, GLP1R is linked to diabetes mellitus.